ArticleBMC cancer2026

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial.

Christoph Schaefers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.